We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily fund signal